Literature DB >> 7744147

Subureteric Teflon injection (STING). Results of a European survey.

P Puri1, G K Ninan, R Surana.   

Abstract

Subureteric Teflon injection (STING) has been successfully used by several investigators for treating vesicoureteric reflux (VUR) in children. This multicentre European survey reviews the results of STING in 6,216 ureters. Twenty-two paediatric surgeons/urologists from 18 centres in Europe answered an enquiry regarding their experience with STING in the treatment of VUR. 6,216 refluxing ureters were injected with Polytef paste in 4,166 children during 1984-1990. There were 975 boys and 3,191 girls. Their ages ranged from 2 months to 14 years (mean 5.1 years). The reflux was grade I in 4.4% of ureters, grade II in 36.1%, grade III in 40.2%, and grades IV and V in 19.3% of ureters. All patients were followed up for periods ranging from 3 months to 81/2 years and 90% were followed up for more than 2 years. 76.3% of all ureters stopped refluxing after a single injection of Teflon paste, cure rate increased to 84.9% after a second injection. A further 10.2% of refluxing ureters showed significant improvement in the grade of reflux after a single injection and needed no further treatment. 1.3% of ureters were cured after a third or fourth injection. Failure to correct or improve VUR was seen in 224 ureters (3.6%), necessitating reimplantation. Twenty ureters (0.32%) developed vesicoureteric junction obstruction following STING and these were reimplanted without difficulty. Results of this multicentre survey confirm that STING is an effective day care procedure for treatment of all grades of VUR. 95% of all ureters were cured or showed significant improvement after two injections of Teflon paste.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744147     DOI: 10.1159/000475128

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  What are the indications for the "Sting" operation for the treatment of vesicoureteric reflux?

Authors: 
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

2.  [Primary vesicoureteral reflux].

Authors:  R Stein; C Ziesel; P Rubenwolf; R Beetz
Journal:  Urologe A       Date:  2013-01       Impact factor: 0.639

3.  Recurrent urinary tract infections in kidney transplant recipients.

Authors:  Subhashis Mitra; George John Alangaden
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

4.  Surgical intervention in children with vesicoureteric reflux: are we intervening too late?

Authors:  Basem A Khalil; Anju Goyal; Alan P Dickson
Journal:  Pediatr Surg Int       Date:  2010-05-29       Impact factor: 1.827

5.  Role of the Teflon deposit in the recurrence of vesicoureteral reflux.

Authors:  Zsolt Oberritter; Reka Somogyi; Zsolt Juhasz; Andrew B Pinter
Journal:  Pediatr Nephrol       Date:  2008-01-16       Impact factor: 3.714

Review 6.  The extended use of deflux (dextranomer/hyaluronic acid) in pediatric urology.

Authors:  Gregory E Dean; Leo R Doumanian
Journal:  Curr Urol Rep       Date:  2006-03       Impact factor: 3.092

Review 7.  A transperitoneal laparoscopic approach to endourology.

Authors:  A M Kaynan; H N Winfield
Journal:  Curr Urol Rep       Date:  2001-04       Impact factor: 2.862

Review 8.  Tissue engineering in urology: where are we going?

Authors:  Adam R Metwalli; James R Colvert; Bradley P Kropp
Journal:  Curr Urol Rep       Date:  2003-04       Impact factor: 2.862

Review 9.  Vesicoureteral reflux: a new treatment algorithm.

Authors:  Arne Stenberg; Terry W Hensle; Göran Läckgren
Journal:  Curr Urol Rep       Date:  2002-04       Impact factor: 2.862

10.  Long-term Outcomes of Endoscopic Anti-reflux Surgery in Pediatric Patients with Vesicoureteral Reflux: Urinary Tract Infection, Renal Scarring, and Predictive Factors for Success.

Authors:  Wonseok Choi; Wook Nam; Chanwoo Lee; Jae Hyeon Han; Jung Hyun Shin; Kun Suk Kim; Sang Hoon Song
Journal:  J Korean Med Sci       Date:  2018-08-08       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.